J
Jean-Luc Laï
Researcher at French Institute of Health and Medical Research
Publications - 142
Citations - 7256
Jean-Luc Laï is an academic researcher from French Institute of Health and Medical Research. The author has contributed to research in topics: Chromosomal translocation & Myeloid leukemia. The author has an hindex of 41, co-authored 142 publications receiving 6907 citations.
Papers
More filters
Journal ArticleDOI
Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment
Catherine Roche-Lestienne,Valérie Soenen-Cornu,Nathalie Grardel-Duflos,Jean-Luc Laï,Nathalie Philippe,Thierry Facon,Pierre Fenaux,Claude Preudhomme +7 more
TL;DR: The data support that in CML patients treated with STI571, ABL mutations are not restricted to the accelerated phase of the disease and that, at least in some cases, mutations seem to occur prior to STi571 therapy, probably as second mutational events during the course of CML.
Journal ArticleDOI
Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system [see comments]
Brigitte Dupriez,Pierre Morel,Jean-Loup Demory,Jean-Luc Laï,Marc A. Simon,Isabelle Plantier,Francis Bauters +6 more
TL;DR: Hemoglobin level and leukocyte count provide a simple prognostic model for survival in AMM, and the adverse prognostic value of abnormal karyotype may be related to a higher rate of acute conversion.
Journal ArticleDOI
Acute myeloid leukemia and myelodysplastic syndromes following essential thrombocythemia treated with hydroxyurea: high proportion of cases with 17p deletion.
Yvon Sterkers,Claude Preudhomme,Jean-Luc Laï,Jean-Loup Demory,M. T. Caulier,Eric Wattel,Dominique Bordessoule,Francis Bauters,Pierre Fenaux +8 more
TL;DR: Results show that treatment with HU alone is associated with a leukemic risk of approximately 3.5%, and suggest that widespread and prolonged use of HU in ET may have to be reconsidered in some situations, such as asymptomatic ET.
Journal Article
Cytogenetic analysis has strong independent prognostic value in de novo myelodysplastic syndromes and can be incorporated in a new scoring system: a report on 408 cases
Pierre Morel,M Hebbar,Jean-Luc Laï,Alain Duhamel,Claude Preudhomme,Eric Wattel,Francis Bauters,Pierre Fenaux +7 more
TL;DR: Although the prognostic value of cytogenetic analysis has previously been demonstrated in myelodysplastic syndromes (MDS), karyotype had not been included in previously published scoring systems, such as Bournemouth and Sanz's scores.
Journal ArticleDOI
Chromosome 13 abnormalities identified by FISH analysis and serum β2-microglobulin produce a powerful myeloma staging system for patients receiving high-dose therapy
Thierry Facon,Hervé Avet-Loiseau,Gaelle Guillerm,Philippe Moreau,Franck Geneviève,Marc Zandecki,Jean-Luc Laï,Xavier Leleu,Jean-Pierre Jouet,Francis Bauters,Jean-Luc Harousseau,Régis Bataille,Jean-Yves Mary +12 more
TL;DR: It is concluded that delta13, adequately detected by FISH analysis, is a very strong factor related to poor survival, especially when associated with a beta2m level of 2.5 mg/L or higher.